A recent study has found that Deucravacitinib can improve outcomes in patients with psoriatic arthritis. The drug showed promising results in reducing symptoms and improving quality of life for individuals with this condition. The study highlights the potential benefits of Deucravacitinib as a treatment option for psoriatic arthritis. By continuing to use the site, you agree to the use of cookies for analytics and advertising purposes. For more information, you can refer to the site’s Cookie Policy and adjust your Cookie Settings accordingly.
Source link
Deucravacitinib improves outcomes in patients with psoriasis arthritis: Study
